The ECLIPSE Study: Efficacy of Cryoablation on Metastatic Lung Tumors With a 5-Year Follow-Up

• DOI: 10.1016/j.jtho.2021.07.021
• Publication Date: 2021-08-09T17:22:14Z
• Authors: Thierry de Baère; David Woodrum; Lambros Tselikas; Fereidoun Abtin; Peter Littrup; Frederic Deschamps; Robert Suh; Hussein D. Aoun; Matthew Callstrom
• Keywords: Cryoablation; Eclipse

IntroductionThe ECLIPSE study aimed to evaluate the feasibility and efficacy of cryoablation (CA) for local tumor control in patients with pulmonary metastatic disease 5 years follow-up.MethodsECLIPSE was a prospective, multicenter, single-arm that included treated CA if they had one five lung tumors, each diameter less than or equal 3.5 cm. Patients were followed up course years. The primary end point control, both per patient; secondary points cancer-specific survival, overall quality life (QoL). QoL evaluated using Karnofsky Performance Score, Eastern Cooperative Oncology Group performance score, Short Form-12 health survey.ResultsThe 40 across four sites (three United States Europe). A total 60 tumors 48 procedures. Overall rates 87.9% (29 33) 79.2% (19 24) tumor, 83.3% (20 75.0% (15 20) patient, at 3 years, respectively. progression throughout duration study. Disease-specific survival rate 74.8% 55.3% whereas 63.2% 46.7%, Patient scores did not reach statistical significance.ConclusionsCA is an effective means long-term tumors.